BI's Nintedanib On Course For Indian Debut
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's nintedanib appears to have inched closer to a potential launch in India for the treatment of idiopathic pulmonary fibrosis (IPF), after a key expert panel recommended its approval with a waiver of local clinical trials.